CRISPR Therapeutics (CRSP) Tops Q4 EPS by 105c
Tweet
Share
E-mail
Get Alerts CRSP Hot Sheet
Join SI Premium – FREE
CRISPR Therapeutics (NASDAQ: CRSP) reported Q4 EPS of $1.10, $1.05 better than the analyst estimate of $0.05.
For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- Alta Mesa Resources (AMR) Misses Q2 EPS by 128c
- King Pharmaceuticals (KG) Misses Q2 EPS by 103c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
